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A flow cytometry-adapted fluorescent antibody to membrane antigen (FAMA) assay to detect IgG antibodies
against varicella-zoster virus (VZV) was developed and tested in 62 serum samples, showing 90.32% accuracy
obtained from a receiver operating characteristic (ROC) curve with a 0.9125 (95% confidence interval [CI],
0.829 to 1.00) area below the curve compared to the result with standard FAMA.
Fluorescent antibody to membrane antigen (FAMA) is con-
sidered to be the gold standard for assessing immunity to
varicella and detects seroconversion after vaccination or
natural disease. Other assays have shown inferior perfor-
mances. The enzyme-linked immunosorbent assay (ELISA),
the most accessible, is not reliable at evaluating individual
protection against varicella (3, 5). Among the other assays,
glycoprotein ELISA (gpELISA) (9) and the latex agglutina-
tion assay have limited availability (5, 7, 9, 12, 14) and may
yield false-positive (2) and false-negative (10) results. Indi-
viduals with positive FAMA titers have a less than 3% risk
of developing varicella after household exposure, while in-
dividuals with negative FAMA titers have a 75% risk (12).
The disadvantages of the FAMA assay are its nonautoma-
tion, subjective interpretation, limited scale, lengthy execu-
tion, and need for specific training (1, 6, 8, 11). There
remains a need for a practical and reproducible assay that
can determine susceptibility to varicella and confirm sero-
conversion following vaccination and exposure.
FAMA test is an immunofluorescence assay that uses un-
fixed varicella-zoster virus (VZV)-infected human embryonic
lung fibroblast (HELF) cells incubated with serial 2-fold dilu-
tions of sera. The cells are then washed, incubated, and exam-
ined using fluorescence microscopy (16).
We developed a flow cytometry-adapted FAMA assay (flow-
FAMA) that uses the same HELF cells (in our case, infected
less than 48 h, with a cytopathic effect of less than 90%).
Similarly to the standard FAMA assay, we incubated the in-
fected cells in 25 l of diluted sera for 30 min, washed the cells
in phosphate-buffered saline (PBS), and incubated them for 30
min in 25 l of diluted fluorescein-conjugated anti-human im-
munoglobulin G. After this second incubation and a second
wash, the flow-FAMA assay process diverged from the original
assay process. Rather than preparing the cells on a slide to be
examined under a microscope, we resuspended the cells in 300
l of calcium/magnesium-negative PBS and transferred them
to flow cytometry tubes. The labeled cells were then analyzed
using a FACSCalibur (BD Sciences, San Jose, CA) and BD
CellQuest software (Becton Dickinson, Franklin Lakes, NJ).
We set a threshold for forward scatter (FSC) at 760 and one
for side scatter (SSC) at 550, and we collected 5,000 events for
each sample.
With the intention of assigning a quantitative value that
corresponded with humoral immunity, we used FlowJo soft-
ware 8.8.4 for Mac (Tree Star Inc., Ashland, OR) to create two
gates (both fixed throughout the experiments), one that ex-
cluded noise and a second that captured events representing
humoral immunity (Fig. 1). By calculating the percentage of
events appearing within the borders of this second gate, we
generated a percent positivity for each sample.
To evaluate flow-FAMA, we blindly tested two group of
samples. Group I (n  20) (samples A to T in Table 1) were
archived sera that had been collected and stored since 1974. Of
these 20 samples, 10 were FAMA positive, obtained from
subjects with a positive history of the disease and no disease
after subsequent exposure, and 10 were FAMA negative, ob-
tained from subjects with no history of varicella or vaccination,
who later developed the clinical disease and FAMA serocon-
version. To evaluate inter- and intra-assay variation, we tested
each sample 5 or 6 times over a period of 4 days: once in
triplicate and two or three times individually.
Group II (n 39) (samples 1 to 39 in Table 1) were samples
that tested as either negative or equivocal using the commer-
cially available ELISA in our hospital. We chose these because
they were “problematic” and typically sent to be tested by
FAMA. The samples were tested in triplicate (on a single day)
and the results averaged (Table 1).
The positive control was a high-titer FAMA-positive serum
sample obtained from a subject with a history of varicella and
documented immunity after repeated exposure. The negative
control was a FAMA-negative serum sample obtained from a
subject with no history of varicella infection or vaccination. An
alternative positive control, a low-titer FAMA-positive sample
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obtained from a vaccinee with no history of the disease, was
included in the analysis.
Statistical analysis was performed using Minitab version
15.1, SPSS version 16.0, and an Excel 11.2.5 2004 version for
Mac. The analysis of interassay and intra-assay variations was
based on group I (n  20). Evaluating the samples run in
triplicate from group I, a Friedman test showed no significant
intra-assay variation (P  0.31). Interassay variation was eval-
uated by analyzing the results of group I samples that were
tested across 3 or 4 different days (we averaged the results from
the 1 day they were run in triplicate). No significant interassay
variation was found between the samples that were measured
across either 3 (P  0.387) or 4 (P  0.154) days.
A comparison between the FAMA and flow-FAMA assays
was done independently by a statistician using a receiver op-
erating characteristic (ROC) curve, with the average percent-
ages of positivity obtained from the flow-adapted FAMA assay
reported as a continuous variable and FAMA results as a
categorical variable. The area under the curve was 0.915 (95%
confidence interval [CI], 0.829 to 1.00) (Fig. 2). We chose a
4.7% positive cutoff between 2 options with the highest ac-
curacy, one that provided higher specificity, and then made a
comparison between results of standard FAMA and flow cy-
tometry-adapted FAMA (Table 2) from which we obtained the
following results: sensitivity, 95.25%; specificity, 80.0%; prev-
alence, 67.74%; and accuracy, 90.32%.
Of the 62 samples measured, we encountered 6 discrepan-
cies between the FAMA and flow-FAMA results. The standard
FAMA test recorded 2 positive results that were negative by
flow-FAMA, obtained from subjects reported as having a his-
tory of clinical varicella. Among the four subjects who tested
positive by flow cytometry-adapted FAMA but negative by
standard FAMA, one had an unknown history regarding vari-
cella or vaccination, another had a negative history of varicella
and no vaccination, and two had histories of varicella but no
vaccination.
Dealing with samples that were troublesome for commer-
cially available antibody assays that do not reliably detect im-
FIG. 1. FAMA positive-control (A) and negative-control (B) gatings using forward scatter (FSC) and fluorescein isothiocyanate (FITC) axes
as templates for analysis. Results are expressed as percentages of positivity inside oval gates (in the right-hand panels).
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TABLE 1. Results obtained with standard FAMA and flow cytometry-adapted FAMA assays
Sample StandardFAMA result
Avg flow-FAMA
result (%) No. of runs Range SD CV
Positive control Positive 25.08 16 21.50–27.18 1.99 7.94
Negative control Negative 1.20 13 0.76–2.50 0.51 42.51
Positive-control vaccinee Positive 11.39 2 10.18–12.59 1.70 14.97
A Positive 6.09 6 2.83–8.35 2.66 43.74
B Positive 19.86 5 17.65–22.36 18.53 9.33
C Positive 19.37 5 13.26–22.19 3.51 18.12
D Positive 21.49 5 19.56–23.52 1.48 6.87
E Positive 22.10 5 20.15–24.36 1.66 7.52
F Positive 14.23 5 12.71–15.95 1.48 10.42
G Positive 10.96 6 9.51–13.09 1.67 15.18
H Positive 12.53 6 9.29–18.29 3.57 28.49
I Positive 15.22 6 11.52–17.12 2.26 14.85
J Positive 13.73 6 10.73–15.84 1.83 13.37
K Negative 1.61 5 1.03–2.35 0.48 29.85
L Negative 1.45 5 0.77–3.29 1.08 74.61
M Negative 2.83 5 0.61–6.85 2.65 93.48
N Negative 3.70 5 1.60–5.07 1.62 43.81
O Negative 2.64 5 1.33–6.04 1.94 73.36
P Negative 3.59 5 2.25–4.86 1.14 31.77
Q Negative 4.65 6 1.88–11.29 3.43 73.84
R Negative 0.76 6 0.49–0.87 0.17 21.95
S Negative 2.11 6 1.39–4.85 1.36 64.25
T Negative 0.73 6 0.28–1.87 0.58 80.11
1 Positive 1.76 3 1.44–2.17 0.37 21.10
2 Positive 4.92 3 4.78–5.03 0.12 2.58
3 Positive 7.56 3 6.47–8.22 0.95 12.57
4 Positive 13.65 3 11.72–14.83 1.69 12.36
5 Positive 4.81 3 3.54–6.09 1.27 26.49
6 Positive 6.28 3 6.01–6.65 0.33 5.28
7 Positive 4.74 3 4.22–5.06 0.46 9.62
8 Positive 14.29 3 13.48–14.77 0.70 4.95
9 Positive 6.58 3 6.13–7.17 0.53 8.09
10 Negative 3.01 3 1.71–3.76 1.13 37.5
11 Positive 11.19 3 10.47–11.70 0.64 5.74
12 Positive 10.17 3 8.46–11.35 1.52 14.92
13 Positive 10.71 3 10.09–11.68 0.85 7.96
14 Positive 5.69 3 5.39–6.24 0.48 8.38
15 Negative 12.40 3 11.89–13.14 0.66 5.30
16 Positive 7.81 3 6.21–9.22 1.51 19.39
17 Negative 5.34 3 5.07–5.49 0.24 4.43
18 Positive 9.19 3 8.66–10.18 0.86 9.37
19 Negative 4.98 3 3.47–5.89 1.32 26.44
20 Positive 11.26 3 9.63–12.65 1.53 13.54
21 Positive 6.14 3 4.97–8.38 1.94 31.60
22 Positive 9.65 3 8.83–10.79 1.02 10.55
23 Positive 13.26 3 12.15–14.10 1.00 7.56
24 Positive 12.43 3 11.6–13.6 1.04 8.39
25 Negative 2.84 3 1.93–3.59 0.84 29.63
26 Negative 0.34 3 0.11–0.54 0.21 64.14
27 Negative 0.76 3 0.71–0.79 0.04 5.50
28 Negative 0.75 3 0.59–0.92 0.17 22.18
29 Positive 9.20 3 8.16–9.97 0.94 10.17
30 Positive 9.67 3 9.21–10.44 0.67 6.93
31 Positive 11.12 3 10.23–11.71 0.78 7.05
32 Positive 7.40 3 6.69–7.89 0.63 8.51
33 Positive 4.03 3 3.51–4.73 0.63 15.67
34 Positive 7.30 3 7.12–7.57 0.24 3.23
35 Positive 8.11 3 7.37–8.94 0.79 9.72
36 Positive 11.88 3 10.55–13.18 1.31 11.07
37 Positive 7.90 3 3.90–11.80 3.66 46.32
38 Positive 10.22 3 9.48–10.99 0.76 7.39
39 Negative 10.84 3 8.88–12.11 1.72 15.90
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munity after vaccination (3, 4, 5, 13, 15), we obtained auto-
mated measurements with a simple monochromatic flow
cytometry procedure and received results comparable to those
of the gold standard FAMA assay. With further efforts toward
simplifying the procedure, we believe the assay could become
a valuable tool for assessing populations at risk of complica-
tions, particularly immunosuppressed subjects, institutional-
ized individuals, and health care professionals.
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FIG. 2. Receiver operating characteristic (ROC) curve obtained from
true positives (Sensitivity) and false positives (1 – Specificity) with different
cutoffs of flow-adapted FAMA assay (results expressed as percentages of
positivity) compared to standard FAMA (either positive or negative results).
TABLE 2. Correlation between standard results obtained
with FAMA and flow-adapted FAMA assays using a
4.7%a cutoff obtained from a receiver operating
characteristic (ROC) curve
Flow-adapted
FAMA result
Standard FAMA result
No. of positive
samples
No. of negative
samples Total
Positive 40 4 44
Negative 2 16 18
Total 42 20 62
a Flow-FAMA result was negative if 4.7% and positive if 4.7%.
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